Cailong Pharmaceutical-IPO Research (No. 158): Leading Brain Protector Pharmaceutical Company
Comments on Cylon Pharmaceutical (002898) Quarterly report: business growth exceeds expectations and follow-up products will be produced.
Cylon Pharmaceutical (002898) New share Analysis: neurosystematized drugs High quality Target layout Digestive systematized Drug Declaration
Research report on New shares of Cylon Pharmaceutical Industry (002898): important Pharmaceutical Enterprises of brain Protective agents in China
Cylon Pharmaceutical (002898) New share report: excellent Pharmaceutical Enterprises with the Development of Cooperative production Mode
Cylon Pharmaceutical (002898) Inquiry report on New shares